Previous 10 | Next 10 |
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial producti...
CoronaVac, the COVID-19 vaccine developed by Sinovac Biotech (NASDAQ:SVA) has shown efficacy against the variants first detected in the U.K. and South Africa, an official from Butantan biomedical center, the company’s Brazilian partner has said.“We have tested this vaccine ...
Sinovac Biotech (SVA) announces that the China National Medical Products Administration ((NMPA)) has granted a conditional marketing authorization ((CMA)) for its CoronaVac COVID-19 vaccine in individuals aged 18 and above.The approval is based on the results of the two-month data of phase II...
Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) t...
Based on results from late-stage trials, Sinovac Biotech (SVA) says its COVID-19 vaccine candidate demonstrated a 100% efficacy against hospitalized, severe, and fatal cases of COVID-19.The randomized, double-blind, and placebo-controlled studies conducted in Brazil and Turkey evaluated the e...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on July 21, 2020. Trial...
Sinovac Biotech (SVA) has officially filed for conditional market authorization for CoronaVac, its COVID-19 vaccine, with China's National Medical Products Administration ((NMPA)).The vaccine candidate was tested in phase III clinical studies outside of China, with preliminary ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has officially filed for conditional market authorization for CoronaVac, the COVID-19 vaccine, with Chinaȁ...
MRK was developing two candidates in this category - with Themis they were working on a measles-based one, and the IAVI a VSV-based one. But the company announced today that they're dropping both of them after looking at the first human Phase I data. Adverse effects in the US, Israel,...
Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. TenNor Therapeutics (Suzhou), a company that develops dual-action antibiotics, announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation ...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...